OCT offers promising new uses for neuro-ophthalmology
August 15th 2004Boston-Optical coherence tomography (OCT), a relatively new technology introduced in 1995, has been getting increasingly greater attention as its usefulness is better appreciated in the areas of retina and glaucoma. Joseph F. Rizzo III, MD, discussed the technology as it applies to neuro-ophthalmic practice.
Ocular motility testing an important part of examination
August 15th 2004Los Angeles-"An assessment of ocular motility is a component of a comprehensive ophthalmologic examination. Therefore, it should be carried out even in the absence of complaints referable to the ocular motor system," said Howard R. Krauss, MD, clinical professor of ophthalmology, Jules Stein Eye Institute, and clinical professor of neurosurgery, UCLA, Los Angeles. "More detailed ocular motor tests can be performed when clinically indicated."
Visual loss of amaruosis fugax can be diagnosed in office
August 15th 2004New York-Differentiating the classic embolic visual loss of amaurosis fugax from the numerous other causes of transient visual loss involves careful evaluation. Mark J. Kupersmith, MD, described how to differentiate among the various causes of transient visual disturbance and target the necessary diagnostic procedures.
Early diagnosis essential in cerebrovascular dissections
August 15th 2004Philadelphia-Cerebrovascular dissection represents a life-and-death situation for the patient. Ophthalmologists should be able to recognize this potentially catastrophic diagnosis and initiate emergent treatment, said Nicholas Volpe, MD.
Sleep apnea linked to some ischemic optic neuropathy cases
August 15th 2004Dallas-A sleep study should be performed in patients who have an elevated C-reactive protein (CRP) level and biopsy-negative ischemic optic neuropathy. Elevated CRP may be a marker for sleep apnea-associated optic neuropathy, according to John G. McHenry, MD.
Glaucoma drug may be useful approach for blepharospasm
August 15th 2004Monterey Park, CA-Latanoprost (Xalatan, Pfizer) may be an alternative treatment for blepharospasm. Ted C. Wei Jr., MD, reported that 75% of his patients had moderate to complete resolution of symptoms after latanoprost was prescribed.
Rule of pupil still applies to complete third-nerve palsy
August 15th 2004St. Louis-When the rule of the pupil was first described in 1958 by Wilbur Rucker, MD, there were specific guidelines to follow if the pupillary reaction was normal and if it was not; in the first case, paralysis is likely due to occlusive vascular disease and in the second case to aneurysm.
New treatment targets seasonal ocular allergic conjunctivitis
August 15th 2004Fort Lauderdale, FL-Ophthalmic epinastine HCl is a new therapy for symptomatic relief of seasonal allergic conjunctivitis that is at least as effective and well tolerated as ketotifen fumarate (Zaditor, Novartis Pharmaceuticals, Duluth, GA), reported Stefano Bonini, MD, at the annual meeting of the Association for Research in Vision and Ophthalmology.
PDT trials for AMD help in timing, patient selection
August 15th 2004Cleveland-A series of ongoing clinical trials helps the clinician better understand the proper timing and selection of photodynamic therapy (PDT) with verteporfin (Visudyne, QLT Phototherapeutics/Novartis Ophthalmics) for age-related macular degeneration (AMD), said Peter K. Kaiser, MD, staff physician at the Cole Eye Institute, Cleveland Clinic Foundation.
Drug delivery device effective in macular edema trial
August 15th 2004Baltimore-A dexamethasone posterior segment drug delivery system (Posurdex, Allergan), developed by Oculex Pharmaceu- ticals, performed well in a phase II trial in patients with macular edema, with a 700-?g dose achieving statistically significant results when compared with an observation-only control group, according to Julia A. Haller, MD.
Surface ablation recommended for irregular astigmatism
August 15th 2004San Diego-Surface ablation techniques such as PRK and LASEK can be considered in eyes with highly irregular astigmatism that have previously undergone LASIK or RK, according to Gustavo E. Tamayo, MD, who spoke during the annual meeting of the American Society of Cataract and Refractive Surgery.
Functional damage is key to monitoring glaucoma
August 15th 2004New York-The ideal monitor of glaucoma progression should have high sensitivity, high specificity, be resistant to fluctuations of the condition, require few confirmatory tests, have broad sensitivity at all stages of the disease, and be easy to interpret, according to David S. Greenfield, MD, who spoke at the Glaucoma 2004 meeting here.
Cyclotorsional registration improves wavefront outcomes
August 15th 2004San Diego-Cyclotorsional registration is an important step to optimize wavefront-guided ablations, according to refractive expert Marguerite B. McDonald, MD, who spoke during the American Society of Cataract and Refractive Surgery annual meeting.
Epi-LASIK procedure could be alternative to LASEK
August 15th 2004Dorado, Puerto Rico-LASEK has certainly gained some proponents over the last couple of years. These surgeons claim that the procedure is less painful and offers quicker visual recovery than PRK and spares tissue and avoids flap complications associated with LASIK.
Three-year results document myopic ICL safety, efficacy
August 15th 2004Eugene, OR-Three-year FDA clinical trial results establish the efficacy of the myopic Implantable Contact Lens (ICL, STAAR Surgical) for correcting –3 to –20 D of myopia and substantiate its overall safety in patients with moderate to high myopia, said I. Howard Fine, MD.
Customized ablation with large optical zones advantageous
August 15th 2004San Diego-In eyes treated with the Zyoptix Customized Ablation System (Bausch & Lomb, Rochester, NY), outcomes analysis demonstrated improvements in contrast sensitivity and higher-order aberrations in eyes treated with large optical zones of 6.5 to 7 mm and in those that had greater higher-order aberrations before treatment.
Nutraceutical with lutein offers expanded health potential
August 15th 2004Norfolk, VA-A new formulation of the oral nutraceutical HydroEye featuring added lutein (HydroEye Plus Lutein, ScienceBased Health) acknowledges the potential benefits of dietary manipulation on ocular disease, emphasizes prevention, and improves cost-effectiveness and compliance for patients, said John D. Sheppard, MD.